AP NEWS

Innovations in Predictive 3D Modeling of Live Human Cells, Vaccine Development, Gene Editing, and Targeted Protein Degradation Platforms, 2018 Study - ResearchAndMarkets.com

December 14, 2018

DUBLIN--(BUSINESS WIRE)--Dec 14, 2018--The “Innovations in Predictive 3D Modeling of Live Human Cells, Vaccine Development, Gene Editing, and Targeted Protein Degradation Platforms” report has been added to ResearchAndMarkets.com’s offering.

This edition of the Genetic Technology TOE depicts life sciences trends across predictive 3D modeling of live human cells, vaccine development, gene editing, and targeted protein degradation platforms. The corresponding clinical trials scenario is also covered.

The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Key Topics Covered:

Recent Advances in Predictive 3D Modeling of Live Human Cells, Vaccine Development, Gene Editing, and Targeted Protein Degradation Platforms

Artificial Intelligence that Delivers Predictive 3D View Inside a Living Human Cell A Potential Vaccine to Suppress Food Allergies Precise Gene Editing with ARCUS Exploiting Ubiquitin Proteosome Mechanism to Drug Undruggable Proteins

Clinical Trial Analysis and Key Contacts

Clinical Trial Analysis of RNAi drugs for Hereditary Amyloidosis Key Contacts

For more information about this report visit https://www.researchandmarkets.com/research/l8xc68/innovations_in?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181214005537/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Vaccines

KEYWORD:

INDUSTRY KEYWORD: HEALTH OTHER HEALTH

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 12/14/2018 03:57 PM/DISC: 12/14/2018 03:57 PM

http://www.businesswire.com/news/home/20181214005537/en

AP RADIO
Update hourly